Findings

What do systematic reviews say?

24 questions · 29 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 24.1%GRADE not reported 9 · 31%Very low 4 · 13.8%Low 2 · 6.9%Moderate 2 · 6.9%High 5 · 17.2%

Summary of findings: levofloxacin for inhalation solution vs tobramycin

Quality of life: change from baseline in CFQ‐R · adults and children aged over 12 with CF and P aeruginosa

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 282 participants
Low

Summary of findings: levofloxacin for inhalation solution vs tobramycin

Survival · adults and children aged over 12 with CF and P aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: levofloxacin for inhalation solution vs tobramycin

Antibiotic resistance: change from baseline in P aeruginosa CFU/g of sputum at week 24 · adults and children aged over 12 with CF and P aeruginosa

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 282 participants
High

Summary of findings: levofloxacin for inhalation solution vs tobramycin

Adverse events: number of treatment‐related adverse events · adults and children aged over 12 with CF and P aeruginosa

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 282 participants
High